Prescribing Information can be found at the bottom of this page.
ITCH IMPROVEMENT WITH ILUMETRI®
Real-world experience shows that patients on ILUMETRI® achieved itch reduction1
Interim analysis of the TILOT study showed that a numerical improvement in VAS itch score (0–10) from baseline to Week 16 was sustained at Week 281*
VAS itch score numerical improvement from baseline to Week 28
Adapted from Tsianakas A, et al. 2020.
A REAL-WORLD CASE OF ITCH IMPROVEMENT WITH ILUMETRI®
Patient case: improvement in itching after 4 injections of ILUMETRI®
Female patient aged 58 years
• Erythematosquamous plaques on the extensor sides of her extremities, lower back and skin folds (axillary, submammary, inguinal)
Results after 4 injections
• Patient reported improvements in pain and itching of her skin
• Significant visual improvement initially on the large-scale plaques on her trunk and extremities
Case documented by Dr Markus Heck, Griesheim.
*Prospective, multicentre, real-world study, which collected data including PASI, BSA, PGA (global, scalp, nail), itch and pain (VAS), DLQI and patient and physician therapy satisfaction.1
DLQI, Dermatology Life Quality Index. LOCF, last observation carried forward. OC, observed case. PASI, Psoriasis Area Severity Index. VAS, visual analogue scale.
Reference1. Tsianakas A, et al. Interim analysis of the non-interventional study TILOT: effectiveness of tildrakizumab in long-term treatment of moderate to severe plaque psoriasis in routine practice. EADV Congress. 29–31 October 2020. Poster: P1336.
UK-ILU-2100074
July 2021